GS 9411

Drug Profile

GS 9411

Alternative Names: GS9411; P-680

Latest Information Update: 10 Aug 2011

Price : $50

At a glance

  • Originator Parion Sciences
  • Developer Gilead Sciences
  • Class
  • Mechanism of Action Epithelial sodium channel-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 10 Aug 2010 Discontinued - Phase-I for Cystic fibrosis in Australia (Inhalation)
  • 10 Aug 2010 Discontinued - Phase-I for Chronic obstructive pulmonary disease in Australia (Inhalation)
  • 10 Aug 2010 Discontinued - Phase-I for Bronchiectasis in Australia (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top